25 Sentences With "synergize with" | Random Sentence Generator

Android 6.0 Marshmallow works with great fluidity here, and its power optimizations synergize with the efficient 820 chip inside to give the G5 satisfyingly long battery life4.

But an important question, he added, "is to what degree could combined psychosocial intervention -- cognitive behavioral intervention, for example -- synergize with or at least augment the pharmacological effect" of ketamine.

It's augmented reality done in the most unintrusive way possible, and I foresee it being a runaway success because of how well it will synergize with Apple's new bezel-less screen and because of how good the early attempts with it have been.

During each turn, you're given a number of different buildings which you can place on the island, and location counts for a lot; what you place them near gives you positive or negative amounts of points based on what they synergize with.

Sake kasu can commonly be found in Japanese food recipes since it has a distinct taste and also contains yeast and enzymes which can synergize with other food ingredients. Marinating food ingredients in sake kasu can increase the amount of inosine-monophosphate, which is one of the substances that contribute to the umami flavor of the dish.

Analysts at the time were generally upbeat about the prospects for the bank. Raymond H. Graber of TowerGroup suggested the bank could synergize with the other operations of Sony Financial. Still, Paul Jamieson of Gomez Advisors warned that customers would have high expectations for Sony Bank, given Sony's existing reputation for the ease of use and elegant design of its products.

Mukhopadhyay was a renowned writer and thinker and combined nationalism with rationalism in his works. He strived to reform Hindu customs and family laws to synergize with modern times. He had an immense knowledge of Sanskrit, as evidenced by his numerous essays, and critiques of Sanskrit literature. He wrote several books for young people, historical novels and fused many different philosophies into characters he portrayed.

Cannabis cofactors have also been linked to lowering body temperature, modulating immune function, and cell protection. The essential oil of cannabis contains many fragrant terpenoids which may synergize with the cannabinoids to produce their unique effects. THC is converted rapidly to 11-hydroxy-THC, which is also pharmacologically active, so the euphoria outlasts measurable THC levels in blood. THC and cannabidiol are neuroprotective antioxidants.

The D-motifs found in MKK7 are highly specific for JNKs, but have a relatively low binding affinity. It was suggested that the motifs of MKK7 can synergize with each other to provide an efficient substrate phosphorylation It has been shown that all three D-motifs are necessary for correct JNK1:MKK7 complex formations, and for the phosphorylation and activation of JNK1 by MKK7.

First-line treatment consists of warming the patient; more persistent/severe cases may be treated with medications such as tramadol, pethidine, clonidine, and nefopam, which work by reducing the shivering threshold temperature and reducing the patient's level of discomfort. As these medications may react and/or synergize with the anesthetic agents employed during the surgery, their use is generally avoided when possible. The anesthetic ketamine can also be used to manage postanesthetic shivering.

The 3rd Alternative thinking involves applying four paradigms: "I See Myself", "I See You", "I Seek You Out", and "I Synergize With You". The first step or paradigm is about coming to know oneself. It is about stepping outside of normal associations and examining personal worth, feelings, and interests. When a person adopts this paradigm and wins the "private victory," he or she is ready to turn toward others, according to Covey's 7 Habits.

These same genes did not show significant expression changes in healthy cells upon treatment with Mdcec. This suggests a degree of specificity which has promise for development of novel cancer therapies. Further supporting therapeutic efficacy, a study of cecropin A affirmed that cecropin A selectively lyses leukemia cells while exerting little effect on normal lymphocytes. In the same study, chemotherapy drugs cytarabine and 5-fluorouracil synergize with cecropin A in vitro to enhance cytotoxic effects on leukemia cells.

In fact, aberrant transcripts from this gene have been found in about half of all esophageal, stomach, and colon carcinomas. Though the exact molecular function of FHIT is still partially unclear, the gene works as a tumor suppressor as it has been demonstrated in animal studies. Furthermore FHIT has been shown to synergize with VHL, another tumor suppressor, in protecting against chemically - induced lung cancer. FHIT also acts as a tumor suppressor of HER2/neu driven breast cancer.

The differentiation and proliferation of CFU-GEMM are promoted by growth factors, such as interleukins and cytokines. IL-3 and GM-CSF as single factors are equally active in stimulating CFU-GEMM, but the combination of both factors produces additive stimulatory effects upon CFU-GEMM. The growth of CFU-GEMM is stimulated by the stem cell factor, or SCF. SCF has been found also to synergize with GM-CSF, IL-6, IL-3, IL-11 or erythropoietin to increase the numbers of CFU-GEMM.

In 2004, SPH television operations SPH MediaWorks was taken over by MediaCorp. However, UnionWorks was not directly affected by the merger. Variety host Quan Yi Fong, and newscasters Helen Cheung (Zhang Haijie) and Wang Yanqing, who left SPH MediaWorks, became regular talkshow guests on UFM 1003's morning drive time show. In an effort to synergize with SPH's other media platforms, UFM 1003 began to host news broadcasts, with daily broadcasts from Lianhe Zaobao, Lianhe Wanbao, Shin Min Daily News, The Straits Times and The New Paper.

While in a town or staging area, a character's skill and attribute selection can be freely modified to construct a "build". Once in a combat zone (such as an explorable area or a PvP arena), the build becomes immutable until the character exits the combat zone and returns to a staging area. Players generally either choose a specific build for a given area or role, or use builds that synergize with the builds of other characters in the party. A player's ability to help the party is based on the way a player's "build" works.

Psoriasis is an auto- inflammatory skin disease characterized by circumscribed, crimson red, silver- scaled, plaque-like inflammatory lesions. Initially, psoriasis was considered to be a Th1-mediated disease since elevated levels of IFN-γ, TNF-α, and IL-12 was found in the serum and lesions of psoriasis patients. However, the finding of IL-17-producing cells as well as IL17A transcripts in the lesions of psoriatic patients suggested that Th17 cells may synergize with Th1 cells in driving the pathology in psoriasis. The levels of IL-17A in the synovium correlate with tissue damage, whereas levels of IFN-γ correlate with protection.

The first p97 inhibitor Eeyarestatin (EerI) was discovered by screening and characterizing compounds that inhibit the degradation of a fluorescence-labeled ERAD substrate. The mechanism of p97 inhibition by EerI is unclear, but when applied to cells, it induces biological phenotypes associated with p97 inhibition such as ERAD inhibition, ER stress elevation, and apoptosis induction. Importantly, EerI displays significant cancer-killing activity in vitro preferentially against cancer cells isolated from patients, and it can synergize with the proteasome inhibitor bortezomib to kill cancer cells. These observations prompt the idea of targeting p97 as a potential cancer therapy.

Thymosin α1 (TA1), a molecule with immune enhancing properties, was the first of the Thymosins to enter clinical trials. It has been approved in China and more than 30 other countries, and has shown great promise in the treatment of severe sepsis, cancer, and a number of other diseases including the potential treatment of cystic fibrosis. Most recently, TA1 has been found to synergize with a check-point inhibitor and further extend the survival of Stage III/IV melanoma patients previously treated with TA1. Thymosin β4 (Tβ4), the second of the Thymosins to reach the clinic, has been shown to accelerate wound healing and the remodeling of injured tissues.

In 2019, NBCUniversal parent company Comcast acquired the British telecom and media conglomerate Sky plc. As a result, the NBC Sports division became a sibling to Sky Sports, a domestic rightsholder of the Premier League in the UK. Sky began to synergize with NBC Sports throughout 2019, beginning with a collaboration with its reporters for coverage of the transfer deadline, and adding a weekday simulcast from its Sky Sports News channel to the daytime lineup of NBCSN. On-air collaboration with Sky Sports intensified with the beginning of the 2019–20 season; as Sky holds the first pick of matches for 12:30 p.m. (Eastern Time) kickoffs under its renewed contract, NBC will be able to air more prominent matches in its early-afternoon broadcasts.

PAC-1 is notable for the unique path it has taken to the clinic, as it is possibly the only cancer drug to first be rigorously evaluated in pet dogs with spontaneous cancer as a prelude to the human clinical trial. In 2010, a study showed PAC-1 to be safe for dogs, and a second study published later that same year reported that a PAC-1 derivative (called S-PAC-1) was well tolerated in a small phase I clinical trial of dogs with lymphoma. More recently, in addition to this single-agent activity PAC-1 has shown to potently synergize with approved cancer drugs, for example with doxorubicin in the treatment of pet dogs with lymphoma and metastatic osteosarcoma, and with temozolomide in treating pet dogs with spontaneous glioma.

Any class-specific Classic cards retired in this manner are eventually replaced with new Classic cards for that class to prevent class card-count imbalances. At the start of Year of the Dragon in April 2019, two legendaries from The Witchwood set that powers up the hero power, Genn Greymayne and Baku the Mooneater, as well as four cards that synergize with those cards, were moved to the Hall of Fame so those cards left the Standard set a year earlier than normal. Prior to the year moniker system, the Reward set consisted of four cards that could only be obtained by completing meta-game achievements in Hearthstone, such as by collecting at least one copy of every "murloc" card in the Basic and Classic sets. As with other Classic cards, these have since been retired to the Hall of Fame, still usable in Wild play and available through crafting.

Similarly, humans with homozygous splice variants in CD79A predicted to result in loss of the transmembrane region and a truncated or absent protein display agammaglobulinemia and no peripheral B cells. The CD79a ITAM tyrosines (human CD79a Tyr188 and Tyr199, mouse CD79a Tyr182 and Tyr193) phosphorylated in response to BCR crosslinking, are critical for binding of Src-homology 2 domain-containing kinases such as spleen tyrosine kinase (Syk) and signal transduction by CD79a. In vivo, the CD79a ITAM tyrosines synergize with the CD79b ITAM tyrosines to mediate the transition from the pro to the pre B cell stage as suggested by the analysis of mice with targeted mutations of the CD79a and CD79b ITAM. Loss of only one of the two functional CD79a/b ITAMs resulted in impaired B cell development but B cell functions such as the T cell independent type II response and BCR mediated calcium flux in the available B cells were intact.

Therefore, by controlling the dosage, one can achieve selectivity between normal and cancerous cells. In addition to its stand-alone activity, PAC-1 has also been shown to markedly synergize with a variety of approved cancer drugs, for example with BRAF and MEK inhibitors in mouse models of melanoma, and with conventional chemotherapeutic agents such as doxorubicin in pet dogs with spontaneous cancers including lymphoma and metastatic osteosarcoma, and with temozolomide in pet dogs with naturally occurring glioma. Vanquish Oncology reported their intention to begin a Phase I human clinical trial in cancer patients to begin in early 2015, and indeed the Phase 1 trial of PAC-1 opened for enrollment in February 2015 (NCT02355535). This trial is being conducted at the University of Illinois Cancer Center in Chicago, at the Sidney Kimmel Cancer Center at Johns Hopkins, and at Regions Hospital in St. Paul, MN. A Phase 1b trial of PAC-1 plus temozolomide opened in late 2017 at the same three sites (NCT03332355); patients with high grade glioma (glioblastoma multiforme (GBM) or anaplastic astrocytoma) after progression following standard first line therapy are eligible for this trial.